22 January 2019 - The political war over prescription drug practices is spawning a frenzy of activity by outside lobbying groups, some with names that mask their ties to industry and one that has gone to great lengths to disguise its origins.

The increase in advertising, advocacy and pressure tactics is aimed at thwarting some efforts to control drug costs proposed in the Democratic-controlled House, such as allowing Medicare to negotiate drug prices, as well as ideas pursued by the Trump administration to curb prices.

The operations of these groups often dovetail with work by corporate lobbying shops. Most, but not all, disclose industry funding sources on their websites.

Read Washington Post article